Moleculin Biotech Inc
MBRX0.267USD
-0.315-54.20%
Cierre 06/20, 16:00（ET）Cotizaciones retrasadas 15 min
3.77MCap. mercado
PérdidaP/E TTM
Más Datos de Moleculin Biotech Inc Compañía
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Información de la empresa
Símbolo de cotizaciónMBRX
Nombre de la empresaMoleculin Biotech Inc
Fecha de salida a bolsaJun 02, 2016
Fundada en2015
Director ejecutivoMr. Walter V. Klemp
Número de empleados17
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 02
Dirección5300 Memorial Dr Ste 950
CiudadHOUSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77007
Teléfono17133005160
Sitio Webhttps://moleculin.com/
Símbolo de cotizaciónMBRX
Fecha de salida a bolsaJun 02, 2016
Fundada en2015
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
8.00K
--
Mr. Robert E. George
Mr. Robert E. George
Independent Director
Independent Director
979.00
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Independent Director
Independent Director
--
--
Mr. Jonathan P. Foster
Mr. Jonathan P. Foster
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Elizabeth A. (Liz) Cermak
Ms. Elizabeth A. (Liz) Cermak
Independent Director
Independent Director
--
--
Dr. Joy Yan, LPN
Dr. Joy Yan, LPN
Independent Director
Independent Director
--
--
Mr. Michael D. Cannon
Mr. Michael D. Cannon
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Walter V. Klemp
Mr. Walter V. Klemp
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
8.00K
--
Mr. Robert E. George
Mr. Robert E. George
Independent Director
Independent Director
979.00
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Independent Director
Independent Director
--
--
Mr. Jonathan P. Foster
Mr. Jonathan P. Foster
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Elizabeth A. (Liz) Cermak
Ms. Elizabeth A. (Liz) Cermak
Independent Director
Independent Director
--
--
Dr. Joy Yan, LPN
Dr. Joy Yan, LPN
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 4 de jun
Actualizado: mié., 4 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Armistice Capital LLC
8.85%
Cetera Investment Advisers LLC
0.50%
Klemp (Walter V.)
0.41%
LPL Financial LLC
0.33%
The Vanguard Group, Inc.
0.22%
Other
89.70%
Accionistas
Accionistas
Proporción
Armistice Capital LLC
8.85%
Cetera Investment Advisers LLC
0.50%
Klemp (Walter V.)
0.41%
LPL Financial LLC
0.33%
The Vanguard Group, Inc.
0.22%
Other
89.70%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
8.86%
Investment Advisor
1.02%
Individual Investor
0.56%
Investment Advisor/Hedge Fund
0.40%
Corporation
0.16%
Venture Capital
0.08%
Bank and Trust
0.07%
Research Firm
0.03%
Other
88.81%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
57
661.71K
4.73%
+46.20K
2024Q4
59
564.93K
7.40%
-45.69K
2024Q3
59
560.84K
19.72%
+96.29K
2024Q2
59
414.10K
17.96%
+17.19K
2024Q1
59
339.02K
15.22%
-103.46K
2023Q4
61
426.81K
19.16%
+202.97K
2023Q3
59
208.67K
10.51%
-20.61K
2023Q2
62
216.12K
10.93%
-59.32K
2023Q1
65
258.04K
13.11%
-14.27K
2022Q4
71
255.76K
13.40%
-6.75K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Armistice Capital LLC
317.59K
2.27%
+27.59K
+9.51%
Dec 31, 2024
Klemp (Walter V.)
57.03K
0.41%
--
--
Mar 28, 2025
LPL Financial LLC
41.22K
0.29%
+5.11K
+14.16%
Dec 31, 2024
The Vanguard Group, Inc.
30.93K
0.22%
-40.47K
-56.68%
Dec 31, 2024
Geode Capital Management, L.L.C.
22.02K
0.16%
+206.00
+0.94%
Dec 31, 2024
AnnaMed, Inc.
15.90K
0.11%
--
--
Mar 28, 2025
BlackRock Institutional Trust Company, N.A.
12.38K
0.09%
-95.00
-0.76%
Dec 31, 2024
Foster (Jonathan P.)
11.36K
0.08%
--
--
Mar 28, 2025
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
Fecha
Tipo
Relación
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
